Mike Schmidt is not yet convinced that Barry Bonds and Roger Clemens took steroids

41 Comments

Mike Schmidt says an awful lot I agree with in this interview with Jim Salisbury of CSNPhilly.com.  He doesn’t like it when people are accused of using PEDs without evidence and he hates the guilt-by-association that is so common when the topic comes up. What’s more, he has no problem with Barry Bonds or Roger Clemens being in the Hall of Fame.

Yep, we’re really on the same page here. But I don’t think even I’d go this far:

“I would not have a problem with Bonds or Clemens,” Schmidt said at Phillies camp. “Here we are convicting them of PED use and we don’t know anything more than we read.”

Schmidt said he’d need to see “a legitimate failed test” to bar a player from election to the Hall of Fame.

“I don’t think anyone that failed a legitimate test should be in,” Schmidt said. “But I’d need to see a legitimate test to know if what we’re talking about was actual fact.”

I’ve read Game of Shadows. I think it’s safe to say that Barry Bonds took steroids, and I think we can say so without a test result.  Clemens may be a bit more dicey, but I don’t think I’d choose to die on Roger Clemens Didn’t Take Steroids Hill in these PED battles we tend to have.

But really, I’d rather err on the side Schmidt is erring on than to fall in with the “eyeball test” crowd.

Report: Nathan Eovaldi drawing interest from at least nine teams

Nathan Eovaldi
Getty Images
5 Comments

Former Red Sox right-hander Nathan Eovaldi is up for grabs this offseason, and Nick Cafardo of the Boston Globe says that as many as nine suitors are interested in bringing the righty aboard. While the Red Sox are eager to retain Eovaldi’s services after his lights-out performance during their recent postseason run, they’ll have to contend with the Brewers, Phillies, Braves, White Sox, Padres, Blue Jays, Giants, and Angels — all of whom are reportedly positioned to offer something for the starter this winter.

It wasn’t all smooth sailing for the 28-year-old in 2018, however. After losing his 2017 season to Tommy John surgery, he underwent an additional procedure to remove loose bodies from his right elbow in March and didn’t make his first appearance until the end of May. He was flipped for lefty reliever Jalen Beeks just prior to the trade deadline and finished his season with a combined 6-7 record in 21 starts, a 3.81 ERA, 1.6 BB/9, and 8.2 SO/9 through 111 innings.

Despite his numerous health issues over the last few years, Eovaldi raised his stock in October after becoming a major contributor during the Red Sox’ championship run. He contributed two quality starts in the ALDS and ALCS and returned in Games 1-3 of the World Series with three lights-out performances in relief — including a six-inning effort in the 18-inning marathon that was Game 3.

A frontrunner has yet to emerge for the righty this offseason, but Cafardo points out that the nine teams listed so far might just be the tip of the iceberg. Still, he won’t be the most sought-after starter on the market, as former Diamondbacks southpaw Patrick Corbin is expected to command an even bigger payday following his career-best 6.0-fWAR performance in 2018.